BOCA RATON, Fla., Aug. 3 /PRNewswire/ -- Breckenridge announced today that it has entered into an agreement with PII (Pharmaceutics International. Inc.), Hunt Valley, MD to develop and manufacture a generic HRT product. Breckenridge filed an ANDA with the FDA in early 2006 and expects to receive FDA Approval and market the product in 2007.
